Antimicrobial resistance trends among Klebsiella pneumoniae associated with urinary tract infections in Crete, Greece, 2017-2022.

Klebsiella pneumoniae is one of the most prevalent bacteria causing urinary tract infections (UTIs). Its increasing resistance to a wide array of antibiotics limits available treatment options. This study investigated the characteristics and trends of antimicrobial resistance in K. pneumoniae isolated from UTIs in Crete, Greece, during 2017 and 2022. Among the 11,946 Enterobacteriaceae isolated from urine specimens, a total of 1,771 K. pneumoniae isolates were identified (14.8%), with an isolation frequency secondary to Escherichia coli (66.3%). K. pneumoniae isolates increased over the years, with a peak in the year 2022. Higher resistance rates were detected in ciprofloxacin (41%), trimethoprim/sulfamethoxazole (TMP/SMX) (38.1%) and nitrofurantoin (33.9%). Resistance to ciprofloxacin, amoxicillin/clavulanic acid, tigecycline, and TMP/SMX significantly increased from 33.7%, 24%, 6%, and 33.1%, respectively, over the years 2017-2019, to 47.8%, 34.2%, 14.3% and 42.8%, respectively, over the period 2020-2022. ESBL production and carbapenem resistance were decreased by 2.2% and 3.7%, respectively, over the two three-year periods (2017-2019 and 2020-2022). Among the 278 carbapenem-resistant K. pneumoniae (CRKP) isolates, 164 (59%), 66 (23.7%), 18 (6.5%) and 16 (5.8%) were positive for KPC, NDM, VIM and OXA-48 enzymes, respectively. Only 14 (5%) isolates harboured two carbapenemase genes, namely 10 (3.6%) both blaNDM and blaVIM, and 4 (1.4%) both blaKPC and blaNDM. Females, inpatients and the elderly were more frequently affected by CRKP. The frequency of multidrug-resistant (MDR) and extensively drug-resistant (XDR) isolates were 32.6% and 7.7%, respectively. Continuous surveillance of local microbial prevalence and monitoring of antimicrobial resistance patterns provide critical information to guide the empiric therapy for UTIs and control the spread of MDR bacteria.

[1]  Abeer O Almazyed,et al.  Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic , 2024, Antibiotics.

[2]  Fatih Çölkesen,et al.  Carbapenem-Resistant Klebsiella pneumoniae Infection and Its Risk Factors in Older Adult Patients , 2023, Clinical interventions in aging.

[3]  H. Faidah,et al.  Prevalence and Antibiogram Pattern of Klebsiella pneumoniae in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience , 2023, Antibiotics.

[4]  M. Jalil,et al.  The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections , 2022, Journal of clinical laboratory analysis.

[5]  V. Jinga,et al.  Does the COVID Pandemic Modify the Antibiotic Resistance of Uropathogens in Female Patients? A New Storm? , 2022, Antibiotics.

[6]  C. Yean,et al.  Global Prevalence of Nosocomial Multidrug-Resistant Klebsiella pneumoniae: A Systematic Review and Meta-Analysis , 2021, Antibiotics.

[7]  I. Costache,et al.  Insights into multidrug-resistant K. pneumoniae urinary tract infections: From susceptibility to mortality , 2021, Experimental and therapeutic medicine.

[8]  I. Galani,et al.  Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies , 2021, Expert review of anti-infective therapy.

[9]  E. Pérez-Nadales,et al.  Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: the impact of inappropriate empirical treatment. , 2019, The Journal of infection.

[10]  J. Rodríguez-Baño,et al.  Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  J. Bazira,et al.  Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda , 2019, International journal of microbiology.

[12]  M. Medina,et al.  An introduction to the epidemiology and burden of urinary tract infections , 2019, Therapeutic advances in urology.

[13]  Prateek Shrivastava,et al.  World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics , 2018 .

[14]  B. Trautner,et al.  Urinary Tract Infection and Asymptomatic Bacteriuria in Older Adults. , 2017, Infectious disease clinics of North America.

[15]  Setegn Eshetie,et al.  Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia , 2015, Antimicrobial Resistance and Infection Control.

[16]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[17]  S. Pournaras,et al.  Modified CLSI Extended-Spectrum β-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various β-Lactamases , 2014, Journal of Clinical Microbiology.

[18]  I. Morrissey,et al.  A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011 , 2013, Pharmaceuticals.

[19]  Hui Wang,et al.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. , 2013, The Lancet. Infectious diseases.

[20]  Alessandra Carattoli,et al.  Plasmids and the spread of resistance. , 2013, International journal of medical microbiology : IJMM.

[21]  M. Falagas,et al.  Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[22]  G. Daikos,et al.  Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions , 2012, Clinical Microbiology Reviews.

[23]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  R. Dhillon,et al.  ESBLs: A Clear and Present Danger? , 2011, Critical care research and practice.

[25]  P. Nordmann,et al.  Multiplex PCR for detection of acquired carbapenemase genes. , 2011, Diagnostic microbiology and infectious disease.

[26]  S. Pournaras,et al.  A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. , 2010, The Journal of antimicrobial chemotherapy.

[27]  P. Nabeth,et al.  Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar, Senegal: a multicenter study. , 2003, Diagnostic microbiology and infectious disease.

[28]  B. Foxman.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. , 2003, Disease-a-month : DM.

[29]  W. Stamm,et al.  Urinary tract infections: disease panorama and challenges. , 2001, The Journal of infectious diseases.

[30]  J Donohoe,et al.  Urinary tract infection in women. , 1995, Irish medical journal.

[31]  N. Mittmann,et al.  Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. , 2016, The Journal of hospital infection.

[32]  S. Thakur,et al.  Prevalence of Multidrug Resistant Enterobacteriaceae and Extended Spectrum β Lactamase Producing Escherichia Coli in Urinary Tract Infection , 2013 .